Max Robotics — Global Service Robot Directory + US Certification

About

Khashayar Esfahani is a leading surgical oncologist whose research focuses on de-escalating treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC). His major contributions center on integrating neoadjuvant chemotherapy with transoral robotic surgery (TORS) to reduce treatment-related toxicities while preserving excellent oncologic outcomes. In his 2023 study on quality of life after this combined approach, Esfahani demonstrated that patients experience significantly fewer long-term adverse effects compared to traditional chemoradiation, a finding with 13 citations that is shaping clinical guidelines. His 2024 work, with 10 citations, directly addresses the critical challenge of distant metastasis—the leading cause of death in HPV-OPSCC patients—by showing that neoadjuvant chemotherapy followed by TORS effectively controls systemic spread while minimizing toxicity. Esfahani’s research is notable for its patient-centered focus, balancing survival with functional preservation. His work has been instrumental in advancing personalized, less morbid treatment protocols, earning him recognition as a key figure in head and neck cancer de-escalation strategies. For students and researchers, Esfahani exemplifies how surgical innovation can improve both outcomes and quality of life in oncology.